BACKGROUND: The expression of panendothelial markers (eg, @entity2280 , @entity2279 , and factor VIII) is not always observed in angiogenic vessels, and such markers are not useful for measuring angiogenesis. In contrast, CD105 is preferentially expressed in angiogenic vessels and thus may be valuable for measuring angiogenesis. We hypothesized that microvessel quantification by means of CD105 might be useful for measuring angiogenesis in the @entity2513 sequence. METHODS: We immunohistochemically investigated 54 cases of @entity2513 using monoclonal antibodies @entity2280 and CD105, and microvessel density (MVD) was counted at x200 magnification. RESULTS: Microvessels positive for @entity2280 were distributed almost uniformly in @entity652 . In contrast, microvessels positive for CD105 were preferentially observed in the surface area of @entity652 . In @entity189 , @entity2280 stained only a proportion of blood vessels that were positive for CD105. No significant difference of MVD for @entity2280 was observed in the @entity2513 sequence. In contrast, an increment of MVD for CD105 from low-grade to high-grade @entity1141 (P <.0001) and that from high-grade @entity1141 to @entity189 (P <.05) was statistically significant. CONCLUSIONS: Assessing neovascularization with CD105 in the process of @entity14 development may thus be a valuable marker for predicting the risk of @entity14 development.

Estimation of angiogenesis with anti-CD105 immunostaining in the process of XXXX development.

@entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas'] @entity2279 :: ('5175', 'Gene') :: ['CD31'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity2280 :: ('947', 'Gene') :: ['CD34'] @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas'] @entity1141 :: ('MESH:C535662', 'Disease') :: ['dysplasia'] @entity2513 :: ('MESH:C563365', 'Disease') :: ['colorectal adenomas and 20 cases of carcinomas', 'colorectal adenoma-carcinoma']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']
